Does a personalized gut diet beat low-FODMAP for IBS?

Yes, and the gap only shows up over time. A year after a six week diet ended, people on a microbiome-guided personalized diet were still about 78 points better than they started on a standard IBS symptom score, while the low-FODMAP group had drifted 29.3 points worse than baseline.

The low-FODMAP diet is the usual dietary treatment for irritable bowel syndrome. It cuts out a group of carbohydrates that ferment in the gut and trigger gas, bloating, and pain. It works, but it is restrictive, and nobody really knows how people do once the dietitian visits stop.

This trial tested a different idea. Instead of giving everyone the same list of foods to avoid, researchers profiled each person’s gut bacteria and built the diet around that profile. Then they stepped back and watched for a full year with no further dietary support, which is the part that makes this study useful.

What the data show

Both diets worked at six weeks. The difference was durability. The personalized diet group held their gains, sitting 82.0 points below baseline at 6 months and 78.3 points below baseline at 12 months on the IBS Severity Scoring System, the standard symptom questionnaire. The low-FODMAP group went the other way and finished 29.3 points above where they started. The gap between the two groups had about a 1 in 1,000 chance of being coincidence (p = 0.001).

Counting responders tells the same story. At 12 months, 62.5% of the personalized diet group counted as responders versus 34.5% on low-FODMAP. In absolute terms that is 28 percentage points more people helped (95% CI 4.2 to 47.7), so the true advantage is very likely somewhere between 4 and 48 points, and in relative terms it is about 81% more responders. Put another way, about 4 people would need the personalized diet instead of low-FODMAP for one extra person to still be doing well a year later. There was about a 3 in 100 chance this difference was coincidence (Fisher p = 0.029).

Quality of life scores and both the anxiety and depression halves of the Hospital Anxiety and Depression Scale also moved in a more favorable direction with the personalized diet. On the bacterial side, the personalized group kept a gain in Shannon alpha diversity, a measure of how many kinds of bacteria live in the gut and how evenly they are spread. That gain was +0.488 at six weeks and still +0.205 at 12 months, each with less than a 1 in 100 chance of being coincidence.

Dr. Kumar’s Take

The interesting result here is not the six week number, it is what happened after everyone was left alone. A treatment that only works while a dietitian is watching is not much of a treatment for a lifelong condition. Low-FODMAP is clearly effective in the short run, and this trial confirms that, but the benefit evaporated once support ended.

The authors call this a hypothesis-generating follow-up, and that label is fair. The confidence range around the 28 point responder gap runs from 4 to 48 percentage points, which is wide enough that the real effect could be modest or large. The microbiome signal is also mixed. The diversity gain held up, but the broader difference in bacterial community composition between groups was small at 6 months (R² = 0.035, p = 0.011) and had faded by 12 months. So the durability is more convincing than the biology behind it.

Study snapshot

This was a multicenter, open-label randomized controlled trial with blinded outcome assessment, meaning participants knew which diet they were on but the people scoring the results did not. Adults had to meet Rome IV criteria, the standard diagnostic checklist for IBS. Everyone completed a six week diet, either personalized or low-FODMAP, then came back at 6 and 12 months with no further dietary intervention in between. Outcomes were the IBS Severity Scoring System, IBS Quality of Life, and the Hospital Anxiety and Depression Scale, and stool samples were sequenced with 16S rRNA to track bacteria.

Safety, limits, and caveats

Open-label design is the main weakness. People knew they had been given a diet built for them personally, and that alone can shift how they rate their own symptoms on a questionnaire. The trial also stopped supporting participants at six weeks, so what happened to their eating over the following year is not captured. The authors are explicit that larger trials powered for long-term clinical and microbiome outcomes are still needed before this changes standard practice.

Practical Takeaways

If you are on a low-FODMAP diet and feel better, do not assume the benefit sticks on its own. This trial found the improvement had reversed a year after support ended.
Ask your dietitian about the reintroduction and personalization phase rather than staying on strict elimination indefinitely, since restriction was not what held up here.
Track your symptoms with a scored questionnaire rather than memory, because both groups improved at six weeks and only a repeated score showed the divergence later.
Treat commercial microbiome testing carefully. This was a supervised research protocol, not an app that reads a stool test and hands you a food list.

FAQs

Should I stop the low-FODMAP diet based on this study?

No. Both diets reduced symptom severity at six weeks, so low-FODMAP still did its job in the short term. What this trial questions is whether that improvement survives a year without support, and in this group it did not. The sensible reading is that low-FODMAP may be a starting point rather than a destination, and that the personalization step deserves more attention than it usually gets.

What does gut bacterial diversity have to do with IBS symptoms?

Diversity is a rough measure of how many different bacterial species live in your gut and how evenly they are represented. Higher diversity is generally associated with a more stable gut ecosystem. In this trial, the personalized diet group held a diversity gain at both six weeks and 12 months, while the broader difference in which bacteria were present between the two groups faded by the end. That means the diversity finding is the more durable microbiome result, but it does not prove diversity caused the symptom relief.

Why does a six week diet still matter a year later?

That is the central puzzle this trial raises rather than answers. Participants received no further dietary intervention after the six week phase, yet the personalized group was still 78.3 points below baseline at 12 months. Either the eating habits stuck better because the diet was less restrictive, or the microbiome shift itself carried forward, or both. The trial was not designed to separate those explanations, which is exactly why the authors call for larger studies.

Bottom Line

Six weeks of a diet built around a person’s own gut bacteria produced IBS relief that was still there a year later, with 62.5% of that group counting as responders versus 34.5% on the standard low-FODMAP diet, an absolute gap of 28 percentage points. The standard diet worked early and then lost ground, ending 29.3 points worse than baseline. This is one open-label trial framed by its own authors as hypothesis-generating, so it is a strong signal rather than a verdict, but it points at the right question: not which diet works this month, but which one is still working next year.

Read the full study